Key facts
- This page summarizes Robert Janssen's Form 4 filing for DYNAVAX TECHNOLOGIES CORP (DVAX).
- 6 reported transactions and 4 derivative rows are listed below.
- Accepted by SEC: 18 Feb 2025, 17:08.
Robert Janssen - 13 Feb 2025 Form 4 Insider Report for DYNAVAX TECHNOLOGIES CORP (DVAX)
- Reporting relationship
- SVP and CMO
- Issuer ticker
- DVAX
- Reported as of
- 13 Feb 2025
- Net transaction value
- -$58,552
- SEC form
- 4
- Accepted by SEC
- 18 Feb 2025, 17:08:12 UTC
- Prior SEC filing
- 12 Feb 2025
- Next SEC filing
- 20 Feb 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Robert Janssen
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Robert Janssen filed Form 4 for DYNAVAX TECHNOLOGIES CORP (DVAX) on 18 Feb 2025.
Change
- Previous filing in this sequence was filed on 12 Feb 2025.
- Current net transaction value: -$58,552.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
DVAX
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +13,000
- Change %
- +21%
- Price
- Shares after
- 74,236
- Date
- 13 Feb 2025
- Ownership
- Direct
- Footnotes
- F1
DVAX
transaction
Common Stock
Tax liability
- Transaction value
- $58,552
- Shares
- -4,614
- Change %
- -6.2%
- Price
- $12.69
- Shares after
- 69,622
- Date
- 13 Feb 2025
- Ownership
- Direct
- Footnotes
- F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
DVAX
transaction
Derivative
Restricted Stock Unit
Award
- Transaction value
- Shares
- +13,000
- Change %
- Price
- Shares after
- 13,000
- Date
- 13 Feb 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 13,000
- Exercise price
- Footnotes
- F1
DVAX
transaction
Derivative
Restricted Stock Unit
Options Exercise
- Transaction value
- Shares
- -13,000
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 13 Feb 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 13,000
- Exercise price
- Footnotes
- F1
DVAX
transaction
Derivative
Stock Options (Right to Buy)
Award
- Transaction value
- Shares
- +55,000
- Change %
- Price
- Shares after
- 55,000
- Date
- 13 Feb 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 55,000
- Exercise price
- $12.69
- Footnotes
- F3
DVAX
transaction
Derivative
Restricted Stock Unit
Award
- Transaction value
- Shares
- +33,333
- Change %
- Price
- Shares after
- 33,333
- Date
- 13 Feb 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 33,333
- Exercise price
- Footnotes
- F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
Each RSU represents a contingent right to receive one share of common stock. These RSUs vested upon the Issuer's achievement of a certain performance condition.
Footnote F2
Shares withheld by Dynavax Technologies Corporation to satisfy tax withholding requirements on vesting of restricted stock units.
Footnote F3
This option grant will vest over three (3) years with one third (1/3) of the shares subject to the option vesting twelve months after the grant date of February 13, 2025, and one thirty-sixth (1/36) of the shares subject to the option vesting each month thereafter.
Footnote F4
Each RSU represents a contingent right to receive one share of common stock. The RSUs vest over three years with 1/3 vesting on each annual anniversary of February 13, 2025.